CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 9,341 enrolled
Drug / intervention
liraglutide +1 moredrug
Likely dose
liraglutide 1.8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01179048
NCT01179048Phase 3Completed
CompareCT.gov

A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events

Novo Nordisk A/S·interventional·Posted Aug 10, 2010·Updated Jul 17, 2019

In Brief

A Phase 3 clinical trial evaluating liraglutide and placebo for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 9,341 participants across 428 sites in 33 countries.

Detailed Summary

This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesAustralia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, Finland, France, Germany, Greece, India, Ireland, Israel, Italy, Mexico, Netherlands, Norway, Poland, Puerto Rico, Romania, Russia, Serbia, South Africa, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), United Arab Emirates, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 10, 2010
Enrollment StartAug 31, 2010
Primary CompletionDec 17, 2015
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 15.9 years ago

Interventions

liraglutidedrug

Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment

placebodrug

Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment